Hyderabad: Ocugen Inc.
partner, Bharat Biotech partner for us and Canada, said on Thursday that it has initiated a rolling submission to Canadian health for the original Covaxin Covaxin Ocugen vaccine which is originally developed originally and that Canadian health will make a decision after reviewing the evidence delivered that Supports safety, efficacy, and quality “The process of revolving submission is recommended and received under the order while the Minister of Health who respects import, sales and drug advertising for relations with Covid-19 and switches to submission of new drugs for Covid-19, which allows the company to Applying for safety and efficacy and information because they are available, “Ocugen said in the submission of regulations to US exchanges” often referred to as a Rolling Review, this allows Canadian health to begin its review immediately, because information continues to enter, to accelerate the overall process of reercing OCUGEN Arsai Submission of Rolls Through its Affiliates, Vaccigen Ltd Health Canada will make a decision after reviewing evidence conveyed that supporting safety, efficacy and quality, “Ocugen added” we thank Kovaxin and their appearance.
forward to work with them so we can offer the possibility of other choices that are safe and effective for use in their struggle against Covid-19 and the Delta variant, “said Dr.
Shankar Musunuri, chairman of the Board, CEO & Co-Founder, Ocugen Inc.
company Based in the US said the submission followed the release of phase-3 clinical test data from Covaxin which showed efficacy and security in almost 25,800 adults, the data showed Covaxin was 778% effective against the symptoms of Covid-19, 934% effective against the severe symptoms of Covid-19 and 652 % Efficacy of the Delta variant